Minimalist biotechnology companies that have just a handful of employees — or even as few as one — are becoming more feasible with the rise of artificial-intelligence tools.Credit: Getty.
How many scientists does it take to discover a drug?
The question came to the fore after news that a biotechnology tech giant armed with an artificial-intelligence assistant, two promising drug leads and just one full-time human employee had been acquired by San Francisco-based Anthropic as part of the AI giant’s expansion into biomedical science.
AI agents run this automated biology lab that sequences DNA and more.
AI agents run this automated biology lab that sequences DNA and more.
In truth, it took many human scientists to develop the molecules that are the mini-company’s star products: two antibodies that are still in the early stages of development and were designed to treat a rare form of muscular dystrophy. The company, Mithril Medicine in Cambridge, Massachusetts, also hired part-time consultants to advise on the project, and paid at least five contract research organizations to conduct experiments. Many more researchers will be needed to carry the drug further, especially if it eventually enters clinical trials. “It takes a village to develop a drug,” says Jeb Keiper, a partner at Third Rock Ventures, a venture-capital firm in Boston, Massachusetts.
Sources indicate that but the news sparked a wave of discussions about whether the one-person biotech is the drug-discovery business model of the future. “We will see more and more of these small teams that are enabled by AI,” says James Zou, a computer scientist who works on biomedical applications of AI at Stanford University in California. “They will be very powerful for identifying good opportunities and moving quickly.”.
Itsy-bitsy biotechs are not a latest concept. Entrepreneur Matt Davidson started his first biotech organization in 2013, nearly a decade before ChatGPT’s public debut. Davidson kept the roster trim for years, with only two full-time employees until the drug he was developing was ready to enter late-stage clinical testing. The company never had a physical laboratory, Davidson indicates. All the lab work was contracted out.
According to recent reports, his current tech giant, Azora Therapeutics in Los Angeles, California, has a whopping five employees. He uses AI more for summarizing reports than for scientific discovery and states that AI tools have made tiny biotechs more efficient. “We use consultants a little bit less than we used to,” he says.
Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next?
Recent findings suggest that anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next?
Mithril Medicine leaned more heavily on AI than Azora does, and tasked Anthropic’s AI assistant Claude with helping to analyse data and suggesting next steps, as well as taming the piles of e-mails and paperwork that come from working with multiple contract research organizations. “What began as an exercise in staying lean evolved into the thesis for an entirely upcoming operating model, which we now call Pipeline-in-a-Person,” wrote Cody Tranbarger, Mithril’s former chief executive and lone employee, on LinkedIn. (Tranbarger, who has worked for Anthropic since Mithril was absorbed into it, declined to speak to Nature, as did Anthropic.).
doi: https://doi.org/10.1038/d41586-026-03640-9.
Industry observers note that zhang, H. G., Eckmann, P., Miao, J., Mahon, A. B. & Zou, J. Science 394, eaeg6779 (2026).
Article Google Scholar.
Four ways to power-up AI for drug discovery.
Are AI tech giants hijacking drug discovery?
Understanding the tech giant landscape in AI-driven biopharma R&D.
AI-powered innovation in drug discovery.
Biotech innovations are an opportunity to limit climate change.
Engineered bacteria are weaning farms away from synthetic fertilizers.
Cholera bacterium’s good deed: inspiring a glue with rare properties.
Conference networking made simple, in three short videos.
AI’s energy paradox: will the AI boom strain energy systems or be the source of solutions?
PhDs worldwide are having a shake up — why now?
UNC13A splice correction rescues synaptic dysfunction induced by TDP-43 loss.
Domain-alteration chimeras rewire oncogenic complexes in prostate cancer.
In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering.
job board:https://apply.interfolio.com/56017/positions.
job board:https://apply.interfolio.com/56017/positions.
Join HZAU's global faculty team to advance research with competitive benefits.
Huazhong Agricultural University (HZAU).
Postdoctoral fellowship in vascular biology at UT Southwestern, studying the endothelial basis of cardiometabolic disease.
MSU Department of Integrative Biology seeks visionary and accomplished scientists for a tenure-system position Associate or Full Professor.
Michigan State University - Department of Integrative Biology.
